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D ESPITE its attended complications. immunosuppres-
sion for graft acceptance and the impending threat of 
chronic rejection are two of the many overwhelming factors 
that have necessitated the implementation of strategies 
aimed at inducing donor-specific tolerance (OST). With the 
postulation that persistence of donor cell chimerism after 
organ transplantation (Tx) may play a notable role in 
allograft acceptance and the establishment of OST,I-3 we 
initiated a prospective clinical trial to deliberately augment 
this phenomenon by peri operative donor bone marrow 
(BM) infusion. We report here the outcome in 198 study 
patients with a follow-up of 5 to 1387 days. Also summa-
rized are the results in 115 allograft recipients who, owing 
to unavailability of consent to retrieve vertebral bodies 
(VB) from the cadaveric donors. were monitored as co eta-
neous controls. 
MATERIALS AND METHODS 
Patients 
Sinee the initiation (June 1992) of this study. ISS organ allograft 
recipients have received a single perioperative infusion of 3-6 x 
\0" BM cells/kg body weight. Additionally. 10 recipients have been 
treated using a modified protocol that rcquired multiple infusions 
nf 1 x 1O" cells/kg body weight/day for 5 consecutive days (days 
0-4) post· Tx. Immunosuppression (IS) in the majority of the 
paticnts was with tacrolimus and steroids. whereas since its ap-
proval for clinical Tx. CellCept has been added to the above 
regimen in 32 study and 15 control patients. As has been reported 
previously:' BM was isolated from the VB of cadaveric donors and 
infused without cryopreservation. Dosc adjustment of routine IS 
was initially adopted to treat episodes of acute cellular rejection. 
whereas the use of OKT3 was reserved for the trcatment of 
steroid-resistant rejection. 
Detection of Chimerism and Determination of In Vitro 
Immune Responses 
Using primers specific for either lilA allele or the sex-determining 
n:gion of the Y (SRY) chromosome (in male ~ kmak: recipients). 
the pn:sence of donor DNA was ascertained periodicallv in Ihe 
I'HMC 01 study and control patients Iw PCR. Furthcrm<lre. ,erial 
immunological nlOl1ltorIng was also performed using 1\11.1< ","IV'. 
RESULTS AND DISCUSSION 
The llltusion of BM was uneventful and all patients are alive 
except IS (lV,) who have succumhed to causes unrcIated to 
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infusion: 13 (11 %) control patients have also died during 
the course of this follow-up. Additionally, grafts in nine 
study and five control patients have also been lost during 
their progressive follow-up. The remaining patients have 
excellent graft function. Although the incidence and sever-
ity of acute cellular rejection were comparable in the 
BM-augmented and control groups, graft-versus-host dis-
ease was witnessed in only two (1 %) study recipients (both 
of liver), which for its resolution required minor dose 
adjustments of routine IS. It is noteworthy that a steroid-
free existence has been achieved in 61 % study and 46% 
control patients who are at least 12 months post-Tx. Of 
greater significance, however, is the observation that a 
statistically higher number of kidney recipients in the study 
group (71 %) was weaned off steroids as compared to 
controls (48%). None of the patients are nevertheless 
IS-independent. 
The incidence of chimerism was much higher (94%) in 
the BM-augmented patients as compared to controls 
(56%). Additionally. using LOA-PCR, the levels of chimer-
ism were found to be at least 10- to 100-fold higher in 
8M-augmented recipients compared to that of controlsK~ 
As has been reported elsewhere in these proceedings 
(Aitouche et al), donor cell chimerism was indeed multilin-
eage, and there was explicit evidence for the presence of 
progenitors of donor dendritic cells in the PBMC of eval-
uated BM-augmented patients. Furthermore, it is our con-
tention that the absence of obliterative bronchiolitis in 
8M-augmented lung recipients and its evolvement in 217 
(29%) surviving control patients who have had a compara-
hie duration of follow-up may herald the heginning of our 
recognition of the salutary etfccts of augmented chimerism 
in allograft recipients. 
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